SCHEMBL1976409

SCHEMBL1976409

COc1cc(-c2cc(=O)c3c(O)c(I)c(OC)cc3o2)ccc1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.59
CYP1B1 Q16678 6/20 0.59
CYP1A2 P05177 4/20 0.59
OPRD1 P41143 1/20 0.59
HDAC6 Q9UBN7 2/20 0.55
CREB1 P16220 1/20 0.55
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
ABCB1 P08183 3/20 0.54
ABCG2 Q9UNQ0 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
AURKA O14965 1/20 0.53
KDR P35968 1/20 0.53
FLT3 P36888 1/20 0.53
AURKB Q96GD4 1/20 0.53
MAPT P10636 4/20 0.52
POLB P06746 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421607 0.95 FLT3 (0.56) CYP1A1CYP1B1CYP1A2OPRD1HDAC6
SCHEMBL1977048 0.90 ABCB1 (0.59) CYP1A1CYP1B1CYP1A2OPRD1HDAC6
SCHEMBL24514602 0.89 CYP1A1 (0.75) CYP1A1CYP1B1CYP1A2OPRD1HDAC6
SCHEMBL1421764 0.87 CYP1B1 (0.76) CYP1A1CYP1B1CYP1A2OPRD1HDAC6
SCHEMBL1976256 0.85 MAPT (0.67) CYP1A1CYP1B1CYP1A2HDAC6BCHE
SCHEMBL24514601 0.85 ABCB1 (0.73) CYP1A1CYP1B1CYP1A2OPRD1ACHE
SCHEMBL24514598 0.84 ABCB1 (0.68) CYP1A1CYP1B1CYP1A2OPRD1ACHE
SCHEMBL7156543 0.83 ABCB1 (0.69) CYP1A1CYP1B1CYP1A2OPRD1ACHE
SCHEMBL1421600 0.83 ABCG2 (0.67) CYP1A1CYP1B1CYP1A2BCHEACHE
SCHEMBL8068919 0.83 ABCB1 (0.73) CYP1A1CYP1B1CYP1A2OPRD1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA CYP1A1 753/4885CYP1B1 684/4885CYP1A2 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.